Soliris (Eculizumab) Injection Approved to Treat Neuromyelitis Optica Spectrum Disorder

FRIDAY, June 28, 2019 — The U.S. Food and Drug Administration has approved Soliris (eculizumab) injection as the first treatment for neuromyelitis optica spectrum disorder (NMOSD), the agency announced Thursday.
Soliris is indicated for…
Source: Topamax